-
公开(公告)号:US20130059810A1
公开(公告)日:2013-03-07
申请号:US13587770
申请日:2012-08-16
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/706 , A61P7/00 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
-
2.
公开(公告)号:US20100292180A1
公开(公告)日:2010-11-18
申请号:US12729116
申请日:2010-03-22
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
摘要: The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.
摘要翻译: 本发明包括用于分离基本上不含其它形式的5-氮杂胞苷的结晶形式I的方法,其中5-氮杂胞苷由下式表示:本发明还包括包含5-氮杂胞苷的形式I的药物组合物。
-
公开(公告)号:US07772199B2
公开(公告)日:2010-08-10
申请号:US11458365
申请日:2006-07-18
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L Silvey
IPC分类号: A61K31/706 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
摘要翻译: 本发明提供5-氮杂胞苷的新型多晶型和假多晶型结晶形式,以及制备所述形式的方法,其中5-氮杂胞苷由下式表示:本发明还包括包含所述形式的药物组合物。
-
公开(公告)号:US08614313B2
公开(公告)日:2013-12-24
申请号:US13587768
申请日:2012-08-16
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/7068 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
-
公开(公告)号:US20090005551A1
公开(公告)日:2009-01-01
申请号:US12208238
申请日:2008-09-10
申请人: Dumitru Ionescu , Peter Blumbergs
发明人: Dumitru Ionescu , Peter Blumbergs
IPC分类号: C07H19/12
CPC分类号: C07H19/12
摘要: The present invention provides a method for the preparation of 5-azacytidine, wherein 5-azacytidine is represented by the structure: The method involves the silylation of 5-azacytosine, followed by the coupling of silylated 5-azacytosine to a protected β-D-ribofuranose derivative. The coupling reaction is catalyzed by trimethylsilyl trifluoromethanesulfonate (TMS-Triflate).
摘要翻译: 本发明提供了制备5-氮杂胞苷的方法,其中5-氮杂胞苷由以下结构表示:该方法包括5-氮杂胞嘧啶的甲硅烷基化,然后将甲硅烷基化的5-氮杂胞嘧啶与保护的β- 呋喃核糖衍生物。 偶联反应由三氟甲磺酸三甲基甲硅烷基酯(TMS-Triflate)催化。
-
公开(公告)号:US06943249B2
公开(公告)日:2005-09-13
申请号:US10390530
申请日:2003-03-17
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/7072 , B01J20060101 , C07D251/10 , C07D253/02 , C07D405/04 , C07H19/12
摘要: The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.
摘要翻译: 本发明包括用于分离基本上不含其它形式的5-氮杂胞苷的结晶形式I的方法,其中5-氮杂胞苷由下式表示:本发明还包括包含5-氮杂胞苷的形式I的药物组合物。
-
7.
公开(公告)号:US08779117B2
公开(公告)日:2014-07-15
申请号:US12787214
申请日:2010-05-25
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/706 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: Provided herein are pharmaceutical compositions or dosage forms comprising crystalline 5-azacytidine monohydrate. The pharmaceutical compositions or dosage forms provided herein may be used for oral administration in the treatment of diseases, including the treatment of myelodysplastic syndromes (MDS).
摘要翻译: 本文提供包含结晶5-氮杂胞苷一水合物的药物组合物或剂型。 本文提供的药物组合物或剂型可用于口服给药以治疗疾病,包括治疗骨髓增生异常综合征(MDS)。
-
公开(公告)号:US08513406B2
公开(公告)日:2013-08-20
申请号:US13587770
申请日:2012-08-16
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/7068 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
摘要翻译: 本发明提供5-氮杂胞苷的新型多晶型和假多晶型结晶形式,以及制备所述形式的方法,其中5-氮杂胞苷由下式表示:本发明还包括包含所述形式的药物组合物。
-
9.
公开(公告)号:US20130059809A1
公开(公告)日:2013-03-07
申请号:US13587768
申请日:2012-08-16
申请人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
发明人: Dumitru Ionescu , Peter Blumbergs , Gary L. Silvey
IPC分类号: A61K31/706 , A61P7/00 , C07H19/12
CPC分类号: A61K31/7068 , A61K31/706 , C07H19/048 , C07H19/12
摘要: The invention provides novel polymorphic and pseudopolymorphic crystalline forms of 5-azacytidine, along with methods for preparing said forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising said forms.
摘要翻译: 本发明提供5-氮杂胞苷的新型多晶型和假多晶型结晶形式,以及制备所述形式的方法,其中5-氮杂胞苷由下式表示:本发明还包括包含所述形式的药物组合物。
-
公开(公告)号:US08058424B2
公开(公告)日:2011-11-15
申请号:US12973701
申请日:2010-12-20
申请人: Dumitru Ionescu , Peter Blumbergs
发明人: Dumitru Ionescu , Peter Blumbergs
CPC分类号: C07H19/12
摘要: The present invention provides a method for the preparation of 5-azacytidine, wherein 5-azacytidine is represented by the structure: The method involves the silylation of 5-azacytosine, followed by the coupling of silylated 5-azacytosine to a protected β-D-ribofuranose derivative. The coupling reaction is catalyzed by trimethylsilyl trifluoromethanesulfonate (TMS-Triflate).
摘要翻译: 本发明提供了制备5-氮杂胞苷的方法,其中5-氮杂胞苷由以下结构表示:该方法包括5-氮杂胞嘧啶的甲硅烷基化,然后将甲硅烷基化的5-氮杂胞嘧啶与保护的B-D - 呋喃核糖衍生物。 偶联反应由三氟甲磺酸三甲基甲硅烷基酯(TMS-Triflate)催化。
-
-
-
-
-
-
-
-
-